TriangleRuxolitinib + Venetoclax (NCT03874052)
Ruxolitinib + Venetoclax trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT03874052). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for acute myeloid leukemia that has returned or has not responded to treatment, in adults.
The idea: add ruxolitinib to venetoclax. One group receives ruxolitinib with venetoclax. Another group also receives azacitidine. The drugs are given in 28 day cycles. Ruxolitinib may stop cancer cell growth by blocking enzymes cells need to grow.
This phase 1 study looks for the maximum tolerated dose of ruxolitinib in each combination, and plans 51 patients. At OHSU Knight Cancer Institute in Portland, Oregon, Jennifer Saultz leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.